Share This Author
Novel naphthalenic ligands with high affinity for the melatonin receptor.
Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
- C. D. Bodinat, B. Guardiola‐Lemaître, E. Mocaër, P. Renard, C. Muńoz, M. Millan
- PsychologyNature Reviews Drug Discovery
- 1 August 2010
Agomelatine (Valdoxan/Thymanax; Servier) was granted marketing authorization in 2009 for the treatment of major depression in Europe, thereby becoming the first approved antidepressant to incorporate a non-monoaminergic mechanism of action.
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties
- B. Guardiola‐Lemaître, C. de Bodinat, P. Delagrange, M. Millan, C. Muńoz, E. Mocaër
- BiologyBritish journal of pharmacology
- 1 August 2014
The present review focuses on the pharmacological properties of this novel antidepressant, strikingly different from that of conventional classes of antidepressants, and opens perspectives towards a better understanding of the physiopathological bases underlying depression.
Cloning and functional analysis of a polymorphic variant of the ovine Mel 1a melatonin receptor.
Effects of SCN lesions on circadian blood pressure rhythm in normotensive and transgenic hypertensive rats.
In nonlesioned TGR(mREN2)27 rats and Sprague-Dawley control rats, the melatonin antagonist S-22365 had no suppressive effect on LD-synchronized circadian rhythmicity, indicating that LD itself may have a stronger influence on the SCN than endogenous melatonin.
Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS)
Effects of melatonin receptor ligands on swim test immobility
- D. Overstreet, O. Puciłowski, Marie-Claire Retton, P. Delagrange, B. Guardiola‐Lemaître
- Biology, PsychologyNeuroreport
- 26 January 1998
Findings suggest that the melatonin receptor agonist S 20304 may have antidepressant potential.
New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent…
- E. Kidd, S. Haj-Dahmane, M. Hamon
- Biology, ChemistryThe Journal of pharmacology and experimental…
- 1 February 1993
In vitro, as well as in vivo, the inhibitory influence of the chroman derivatives on the discharge frequency of serotoninergic neurons could be competitively antagonized by (+/-)-tertatolol.